Introduction
============

Bile duct carcinomas, or cholangiocarcinomas, account for 3% of all gastrointestinal cancers worldwide \[[@b1-crt-2017-595]\], and their incidence is higher in Eastern Asian countries, including Korea, China, and Thailand \[[@b2-crt-2017-595]\]. Bile duct carcinomas can be further classified as intrahepatic, perihilar, and distal bile duct carcinomas (DBDCs) \[[@b3-crt-2017-595]\], and DBDCs compromise about 30% of all bile duct carcinomas \[[@b3-crt-2017-595]\]. In the United States, it is estimated that about 10,910 Americans will be diagnosed with carcinomas of the gallbladder and extrahepatic bile duct in 2015 \[[@b4-crt-2017-595]\].

Although the American Joint Committee on Cancer (AJCC) has changed the staging system of extrahepatic bile duct (EBD) carcinoma seven times in the last decades \[[@b5-crt-2017-595],[@b6-crt-2017-595]\], those staging systems have been criticized for being inaccurate in estimating prognosis \[[@b7-crt-2017-595]-[@b9-crt-2017-595]\]. First, the previous staging systems did not take into consideration the histologic characteristics of smooth muscle distribution in the EBD. Cancer staging of DBDCs was separated from the staging of proximal or perihilar bile duct carcinoma from the seventh edition of the AJCC staging manual \[[@b10-crt-2017-595]\]. However, the terminology used in the sixth and seventh editions of the AJCC staging system, which defined T1 and T2 diseases as "confined to the bile duct histologically" and "beyond the wall of the bile duct," was unclear and problematic \[[@b10-crt-2017-595],[@b11-crt-2017-595]\], especially when marked stromal response of the invasive carcinoma presents and obscures the lower boundary of the bile duct wall \[[@b8-crt-2017-595]\]. To overcome the problems of the previous editions of the AJCC cancer staging system for DBDC, an alternative method of T classification was proposed, which measured the depth of tumor invasion from the basal lamina of the adjacent normal epithelium to the most deeply infiltrating tumor cells, and categorized invasion depth as T1, \< 5 mm; T2, 5-12 mm; and T3, \> 12 mm \[[@b12-crt-2017-595]\]. This method more powerfully predicted survival in patients with DBDCs than the previously used T classification of seventh edition \[[@b9-crt-2017-595],[@b12-crt-2017-595],[@b13-crt-2017-595]\], and was ultimately incorporated in the T category of the eighth edition \[[@b14-crt-2017-595]\].

Conversely, the N category of seventh edition AJCC staging system was simple to evaluate the presence or absence of metastatic nodes. Several later studies demonstrated the characteristics of nodal metastasis, including location of the involved lymph nodes, lymphatic spread, and micrometastasis \[[@b15-crt-2017-595]-[@b20-crt-2017-595]\]. Previous studies by Moon et al. \[[@b13-crt-2017-595]\] and Schwarz et al. \[[@b21-crt-2017-595]\] demonstrated that a minimum of 10 lymph nodes were required to assess the accurate N category of DBDC. In addition, several studies emphasized the significance of the 3 tiers of N classification as a prognostic indicator \[[@b13-crt-2017-595],[@b22-crt-2017-595],[@b23-crt-2017-595]\].

In the eighth edition of the AJCC cancer staging for DBDC, the T category was changed according to invasion depth as follows: T1, \< 5 mm; T2, 5-12 mm; and T3, \> 12 mm. The N category was classified into 3-tiers based on the number of metastatic nodes: N0, no nodal metastasis; N1, 1 to 3 nodal metastases; and N2, 4 or more nodal metastases. A summary of the changes between the seventh and eighth editions of AJCC staging for DBDCs is described in [Table 1](#t1-crt-2017-595){ref-type="table"}. Recently, Gonzalez et al. \[[@b1-crt-2017-595]\] reported a size-based T category for staging DBDCs and revealed its significant relationship with patient survival differences, specifically for intra-pancreatic type DBDCs. They stratified 47 intra-pancreatic DBDC cases based on tumor size as follows: \< 2 cm, 2-4 cm, and \> 4 cm \[[@b1-crt-2017-595]\].

To validate the new eighth edition of the AJCC cancer staging system for DBDCs, we compared the clinicopathologic factors including patient survival based on the seventh and eighth editions of the AJCC cancer staging system for DBDC. In addition, we evaluated the prognostic relevance of size-based criteria for the staging for DBDC.

Materials and Methods
=====================

1. Case selection
-----------------

All cases of surgically resected primary DBDCs between May 2010 and June 2012 from Asan Medical Center were collected. Carcinomas originating in the mucosa of the bile duct and from the junction of the cystic duct-common bile duct to the ampulla of Vater were included in this study. Carcinomas arising in the ampulla of Vater or pancreas were excluded. Finally, 200 cases of DBDCs were included in this study.

Clinical data included patient sex and age, operation date, most recent follow-up date, operation method, postoperative radiation therapy and chemotherapy, and survival status. Pathological data included tumor size and location, growth pattern (papillary, nodular, or diffusely infiltrative pattern), histologic subtype, tumor grade, margin status, perineural and lymphovascular invasion, pancreatic, duodenal, and gallbladder invasion, nodal metastasis, and stage grouping evaluation based on the seventh and eighth editions of the AJCC cancer staging system \[[@b10-crt-2017-595],[@b14-crt-2017-595]\]. Tumor size was grossly evaluated and microscopically confirmed. When the discrepancy was present between two measurements, tumor size by microscopic measurement was selected, which was previously described elsewhere \[[@b1-crt-2017-595]\]. The tumor size was further categorized based on greatest dimension as follows: \< 2 cm, 2-4 cm, and \> 4 cm \[[@b1-crt-2017-595]\].

The depth of cancer invasion was measured on slides containing the primary DBDC and was defined as the area of deepest infiltration from the mucosal surface, e.g., from the basal lamina of the adjacent normal epithelium to the most deeply advanced tumor cells. For cases containing high grade dysplasia (or biliary intraepithelial neoplasia \[BilIN\]-3) at the periphery of the invasive tumors, the basal lamina of the high grade dysplasia (or BilIN-3) was used as the reference, which was previously described \[[@b12-crt-2017-595]\]. The maximum depth of tumor invasion was categorized into 3 groups: T1, \< 5 mm; T2, 5-12 mm; and T3, \> 12 mm \[[@b7-crt-2017-595],[@b12-crt-2017-595]\].

DBDCs were further classified based on location in the distal bile duct (DBD) as follows: When the tumor was located within the intrapancreatic DBD, the tumor was classified as "intra-pancreatic type"; when the tumor was located in the DBD outside of the pancreas between the junction of cystic duct-common bile duct to just before entering intra-pancreatic DBD, the tumor was classified as "extra-pancreatic type"; when the tumor diffusely involved intra- and extra-pancreatic DBDs, the tumor was classified as "both intra- and extrapancreatic type" ([Fig. 1](#f1-crt-2017-595){ref-type="fig"}). Tumor grading was classified as low (well to moderately differentiated tumors) and high grade (poorly differentiated and undifferentiated tumors) \[[@b24-crt-2017-595]\].

2. Statistical analysis
-----------------------

Statistical analyses were performed with SPSS software ver. 17.0 (SPSS Inc., Chicago, IL). Categorical data were analyzed using Student's t test, the chi-square test, or Fisher\'s exact test. The survival rate was estimated using the Kaplan-Meier method and the log-rank test was used to calculate its associations with various clinicopathologic factors. The significance of any prognostic factors was investigated with the Cox proportional hazards model. p-values of \< 0.05 were considered to denote statistical significance.

3. Ethical statement
--------------------

The Institutional Review Board of Asan Medical Center approved this study (2013-0527) with a waiver of the informed consent.

Results
=======

1. Patient characteristics
--------------------------

Patient clinicopathologic characteristics are summarized in [Table 2](#t2-crt-2017-595){ref-type="table"}. The male to female ratio of the patients was 2.2 with a median age at resection of 67.0 years (range, 35 to 82 years). There were 168 intra-pancreatic (84.0%), 30 extra-pancreatic (15.0%), and 2 both intra- and extra-pancreatic (1.0%) DBDCs. The mean tumor size was 2.9±1.2 cm. About two-thirds of the cases were between 2 and 4 cm (132/200, 66.0%). One hundred seventy cases (85.0%) were pancreatoduodenectomy specimens including Whipple operation or pylorus-preserving pancreaticoduodenectomy, and the remaining 30 (15.0%) were specimens of bile duct resection with cholecystectomy. Post-operative radiation therapy and chemotherapy were performed in 37 (18.5%) and 69 (34.5%) patients, respectively. In the pathologic examination of bile duct resection specimens, the status of pancreatic or duodenal involvement by the tumor could not be completely evaluated. Consequently, involvements of the pancreas, duodenum, and/or cystic duct of the gallbladder was observed in 68.8% (117/170 cases), 31.8% (54/170), and 18.5% (37/200), respectively, with either single or multiple organ involvement. Lymphovascular and perineural invasions were frequently observed in 40.5% (n=81) and 83.0% (n=166) of cases, respectively. Involvement of resection margin of the bile duct by cancer was in 20.0% (n=40) of cases. The median follow-up period after surgical resection was 33.8 months (range, 1 to 63 months).

2. Comparison between T and N categories of the eighth AJCC and clinicopathologic factors
-----------------------------------------------------------------------------------------

The associations between T and N categories of the eighth AJCC cancer staging scheme and clinicopathologic factors of patients with DBDCs are shown in [Table 3](#t3-crt-2017-595){ref-type="table"}. The patients with higher T category tended to have diffusely infiltrative pattern (p \< 0.001), larger tumor (p=0.022), and presence of perineural (p \< 0.001), lymphovascular (p=0.001), pancreatic (p \< 0.001), and duodenal (p \< 0.001) invasions. In addition, strong association was observed between T and N categories (p \< 0.001).

Similarly, the patients with higher N category tended to have more frequent lymphovascular (p=0.002), pancreatic (p=0.034), and duodenal (p \< 0.001) invasions.

3. Patient survival based on T category
---------------------------------------

The median depth of invasion of DBDC was 8.0 mm (range, 1 to 28 mm). According to the eighth AJCC staging system, 37 cases were categorized as T1 (18.5%), 114 as T2 (57.0%), and 49 as T3 (24.5%) tumors. The median survival time in patients with T2 and T3 tumors was 36.3 months and 19.9 months, respectively, while the median survival time in those with T1 was not reached. The 1-year, 3-year, and 5-year survival rates (YSRs) of patients with T1 tumors were 97.2%, 80.3%, and 59.3%, respectively; conversely, those of patients with T2 tumors were significantly decreased at 86.0%, 50.4%, and 42.4%, respectively. The 1-, 3-, and 5-YSRs of patients with T3 tumors were also significantly decreased at 65.3%, 28.6%, and 12.2%, respectively. Patients with DBDCs showed an overall significant survival difference based on the T category of the eighth edition scheme (p \< 0.001) ([Fig. 2A](#f2-crt-2017-595){ref-type="fig"}). When pairwise comparisons were performed, all pairs of T category showed significant differences in patient survival from each other (T1 and T2, p=0.011; T2 and T3, p \< 0.001).

Conversely, based on the seventh AJCC staging system, 12 were categorized as T1 (6.0%), 40 as T2 (20.0%), and 148 as T3 (74.0%) tumors. The median survival times in patients with T2 and T3 tumors were 41.2 months and 27.5 months, respectively, while the median survival time in those with T1 was not reached. The 1-, 3-, and 5-YSRs were all 91.7% in patients with T1 tumors, 92.5%, 69.7%, and 40.8% in patients with T2 tumors, and 79.6%, 41.7%, and 32.0% in patients with T3 tumors, respectively. Patients with DBDCs showed an overall significant survival difference based on the T category of the seventh edition AJCC staging scheme (p=0.003) ([Fig. 2B](#f2-crt-2017-595){ref-type="fig"}). The pairwise comparisons showed a significant difference between patients with T1 and T2 tumors (p=0.023); however, there was no significant survival difference between patients with T2 and T3 tumors (p=0.066).

4. Patient survival based on N category
---------------------------------------

The total number of examined nodes assessed ranged from 1 to 36 (mean, 12.1±7.5; median, 11.0). Among them, the number of metastatic nodes ranged from 0 to 11 (mean, 0.9±1.9; median, 0). The majority of the tumors were N0 (133 cases, 66.5%). According to the eighth AJCC staging system, nodal metastasis was seen in 67 cases, including 50 N1 (25.0%) and 17 N2 (8.5%). Survival curves based on the N category are depicted in [Fig. 2C](#f2-crt-2017-595){ref-type="fig"} and [D](#f2-crt-2017-595){ref-type="fig"}. The 1-, 3-, and 5-YSRs in patients with N0 tumors were 90.2%, 61.1%, and 47.3%, respectively. Those in patients with N1 and N2 tumors were decreased, corresponding to 68.0%, 34.0%, and 17.0% in N1 patients and 70.6%, 14.7%, and 14.7% in N2 patients, respectively. Overall patient survival was significantly decreased among patients with metastatic nodes (p \< 0.001) ([Fig. 2C](#f2-crt-2017-595){ref-type="fig"}). The median survival times of patients with N1 and N2 tumors (18.8 and 17.0 months, respectively) were significantly shorter than that of patients with N0 (51.8 months; p \< 0.001, each). However, the survival times of the patients with N1 and N2 tumors were not significantly different (p=0.579). The median survival time of the patients with metastatic nodes (18.0 months) was significantly shorter than that of those without metastatic nodes (51.8 months; p \< 0.001). Therefore, patient survival was significantly decreased when the patients had metastatic nodes as defined by the seventh edition scheme ([Fig. 2D](#f2-crt-2017-595){ref-type="fig"}).

5. Patient survival based on AJCC stage grouping
------------------------------------------------

By the eighth edition definitions, the tumors were classified into stages I (33 cases, 16.5%), IIA (85, 42.5%), IIB (65, 32.5%), and IIIA (17, 8.5%). Neither stages IIIB nor IV were seen among our cases. The stage grouping of the new eighth edition was a strong predictor of long-term outcome (p \< 0.001) ([Fig. 3A](#f3-crt-2017-595){ref-type="fig"}). By pairwise comparisons, the 5-YSR of stage IIA patients was significantly better than that of stage IIB patients (p \< 0.001). However, other pairs of stage groupings showed no significant differences in patient survival (stages I and IIA, p=0.148; IIB and IIIA, p=0.691), corresponding to the 5-YSRs of 59.0%, 52.4%, 12.9%, and 14.7% for patients with stage I, IIA, IIB, and IIIA tumors, respectively. After simplifying the stage grouping, patients with stages II and III tumors had a median survival of 31.6 and 17.0 months, respectively. The median survival of patients with stage I tumors had not been reached, because more than 50% of the patient were still alive. Consequently, patients with higher stage tumors tended to have significantly shorter survival (p \< 0.001) ([Fig. 3B](#f3-crt-2017-595){ref-type="fig"}). When pairwise comparisons were performed, all pairs of stages were significantly correlated to patient survival (stages I and II, p=0.002; II and III, p=0.015). This corresponded to a 5-YSR of 35.4% and 14.7% for patients with stage II and III tumors, respectively, and 59.0% for those with stage I tumors.

On the contrary, survival of the seventh AJCC stage grouping is presented in [Fig. 3C](#f3-crt-2017-595){ref-type="fig"} and [D](#f3-crt-2017-595){ref-type="fig"}. As noted in [Fig. 3C](#f3-crt-2017-595){ref-type="fig"}, the seventh AJCC stage grouping also had a good ability to discriminate survival outcome in overall comparison. (p \< 0.001). In brief, the 5-YSR of patients with stage IA tumors (91.7%) was significantly better than that of patients with stage IB (47.8%, p=0.032), and patients with stage IIA tumors (41.0%) had significantly better 5-YSR than those with stage IIB (17.4%, p \< 0.001). However, no significant difference in patient survival was observed between patients with stages IB and IIA (p=0.487). After simplifying the stage grouping, only stages I and II were identified. Finally, patients with stage I tumors had a tendency for longer survival than those with stage II tumors (p=0.002) ([Fig. 3D](#f3-crt-2017-595){ref-type="fig"}), corresponding to a 5-YSR of 59.9% and 31.1% for patients with stage I and II tumors, respectively.

6. Patient survival based on tumor size
---------------------------------------

Among patients with DBDCs (n=200), about two-thirds of the tumors (132 cases, 66.0%) were between 2 and 4 cm in size. Thirty-nine cases (19.5%) had tumors \< 2 cm in size and 29 (14.5%) were \> 4 cm. The patients with a tumor size \< 2 cm had better 5-YSRs (54.6%) than those with tumors between 2 and 4 cm (35.4%), which displayed no significant difference in survival outcomes according to size-criteria (p=0.080) ([Fig. 4A](#f4-crt-2017-595){ref-type="fig"}).

Among intra-pancreatic type tumors (n=168), similar to the above, 115 (68.4%) were between 2 and 4 cm in size. Twenty-eight (16.7%) cases had tumors \< 2 cm in size and 25 (14.9%) were \> 4 cm. Although we analyzed survival in patients with intra-pancreatic type DBDCs only, we could not identify a statistical significance in terms of size-based classification (p=0.164) ([Fig. 4B](#f4-crt-2017-595){ref-type="fig"}).

Conversely, among patients with extra-pancreatic type tumors (n=30), larger tumor size (\> 4 cm) was related to worse patient survival (p=0.039) ([Fig. 4C](#f4-crt-2017-595){ref-type="fig"}). There were 11 (36.7%) tumors \< 2 cm in size, 17 (56.7%) tumors between 2 and 4 cm, and 2 (6.6%) tumors that were \> 4 cm. Both patients with tumor size \> 4 cm died before 1.4 years after surgery. The 5-YSRs of patients with tumor size \< 2 cm and 2 to 4 cm were 43.6% and 9.8%, respectively. By pairwise comparison, a significant difference was seen between patients with tumors between 2 and 4 cm in size and those with \> 4 cm (p=0.011); however, there was no significant difference in the survival of patients with tumors \< 2 cm in size and those between 2 and 4 cm (p=0.126).

7. Univariate and multivariate analyses
---------------------------------------

By univariate analysis, there were no significant differences in survival based on the following: age, sex, postoperative radiation therapy and/or chemotherapy, specified location and size of the tumor, histologic subtype, differentiation, perineural invasion, and gallbladder involvement. However, the following clinicopathologic factors were associated with worse survival of DBDC patients ([Table 4](#t4-crt-2017-595){ref-type="table"}): diffusely infiltrative growth pattern (p=0.001), involvement of bile duct resection margin (p=0.001), the presence of lymphovascular (p=0.022), pancreatic (p \< 0.001), and duodenal invasions (p=0.003), and T and N categories (p \< 0.001, each). By multivariate analysis, lower T (p=0.014) and N (p=0.029) categories and the absence of pancreatic invasion (p=0.006) were good independent prognostic predictors of overall survival in DBDC patients.

Discussion
==========

Our present study validates the new eighth edition of the AJCC staging system in patients with DBDC and reveals that it was superior to the seventh edition in terms of predicting patient prognosis.

For any given malignancy, TNM staging is one of the most powerful prognostic indicators of disease-specific survival. In general, the pathologic T category is defined by anatomic and histologic findings. The hollow viscus organs in the gastrointestinal tract have a well-defined anatomic layering, so it is easier to clarify T classification by anatomic layering, for example, the lamina propria, muscularis mucosa, submucosa, muscularis propria, subserosa, and serosa. However, for the biliary tree, it is difficult to define the bile duct boundary with obvious anatomic descriptions owing to a thin wall, sparse and incomplete smooth muscle, and abundant vascular and neural networks of periductal adipose tissue \[[@b8-crt-2017-595]\]. Moreover, particularly in cancer status, the bile duct boundary is commonly obscured by desmoplastic reactions and inflammation, which makes the distinction between T2 and T3 of the seventh edition AJCC more difficult in DBDC \[[@b7-crt-2017-595]\]. In addition to a problematic and unclear anatomic definition, the T category of the seventh edition AJCC staging system failed to reveal a significant relationship with patient outcome \[[@b7-crt-2017-595],[@b13-crt-2017-595]\]. Conversely, the progressive new T category of the eighth AJCC for DBDC can be applied objectively and has shown reliable results in the prediction of patient outcome \[[@b9-crt-2017-595],[@b12-crt-2017-595],[@b13-crt-2017-595]\]. The predictive role of the T category of the eighth edition AJCC staging system for DBDC in terms of patient prognosis has been described in a few studies conducted in Western \[[@b9-crt-2017-595]\] and Eastern \[[@b13-crt-2017-595]\] countries. Previously, our group proposed a new T category measuring the depth of invasion in DBDCs and demonstrated its strong correlation with patient survival \[[@b9-crt-2017-595]\]. A validation study by Moon et al. \[[@b13-crt-2017-595]\] also reported that the T category of the eighth AJCC for DBDC was significantly associated with patient survival (p \< 0.001) \[[@b13-crt-2017-595]\]. However, they did not observe a difference in survival among patients with T2 and T3 tumors (p=0.16), albeit differences were observed between T1 and T2 tumors (p=0.004). On the contrary, we revealed that the T category of the eighth AJCC staging system for DBDC discriminated patient survival in both pairwise (T1 and T2, p=0.011; T2 and T3, p \< 0.001) and overall (p \< 0.001) comparisons. This discrepancy may be related to the small number of T3 cases (13/117, 11.7%) analyzed in the previous study \[[@b13-crt-2017-595]\].

We also evaluated survival difference by Gonzalez's sizebased criteria for staging in our DBDC cases, but could not find any survival differences. Based on our observations, the sized-based proposal by Gonzalez et al. \[[@b1-crt-2017-595]\] did not segregate patient survival of DBDCs. This result suggested that a T category based on invasion depth has more important survival implications than a T category based on cancer size in DBDCs, similar to T categories of other hollow viscus organs, such as stomach and colorectal cancers.

Several groups demonstrated a minimum of 10 lymph nodes should be examined for the precise evaluation of nodal status of DBDCs \[[@b13-crt-2017-595],[@b21-crt-2017-595]\]. Schwartz and Smith analyzed the Surveillance, Epidemiology, and End Results (SEER) data and demonstrated that patient survival was strongly influenced by the total examined lymph node count \[[@b21-crt-2017-595]\]. Moon et al. \[[@b13-crt-2017-595]\] evaluated various cut-off values according to the number of total lymph nodes examined using 111 cases and revealed the cut-off value was 10 (1 to 9 vs. ≥ 10 of total number of nodes assessed) for differentiating patient survival time \[[@b13-crt-2017-595]\]. On the contrary, our group previously concluded that increasing retrieval of nodes does not affect patient survival in EBD carcinomas, but this study contained both perihilar cholangiocarcinomas and DBDCs and did not discriminate patient survival \[[@b22-crt-2017-595]\]. Therefore, we investigated the difference in patient survival time between groups with 1 to 9 and 10 or more lymph nodes examined, using our present cases; however, no statistically significant differences were observed between the two groups (p=0.670, data not shown).

Including our present study, several previous studies demonstrated the prognostic significance of the 3 tiered N category \[[@b13-crt-2017-595],[@b22-crt-2017-595],[@b23-crt-2017-595],[@b25-crt-2017-595]\]. In present study, we observed significant survival differences among DBDC patients based on N category of the eighth AJCC staging system in overall comparison and in pairwise comparison between N0 and N1 patients, similar to the previous studies \[[@b13-crt-2017-595],[@b22-crt-2017-595],[@b23-crt-2017-595],[@b25-crt-2017-595]\]. However, there are discrepant results of patients' survival between N1 and N2 groups. We did not find significant survival difference between N1 and N2 patients, which was concordant with that of Kang et al.\'s study \[[@b25-crt-2017-595]\]. However, different with the present study, previous results of Moon et al. \[[@b13-crt-2017-595]\] and Kiriyama et al. \[[@b23-crt-2017-595]\] demonstrated significant differences in survival between patients with N1 and N2 tumors \[[@b13-crt-2017-595],[@b23-crt-2017-595]\]. Due to this discrepancy in patients' survival analysis between N1 and N2 groups, further multi-center studies with large number of cases are required for validating N category of the eighth AJCC staging system.

Our group previously proposed a different cutoff for nodal classification, comprising group 1 (no nodal metastasis), group 2 (1-4 nodal metastases), and group 3 (≥ 5 nodal metastases) \[[@b22-crt-2017-595]\]. However, our previous study included both perihilar cholangiocarcinomas and DBDCs \[[@b22-crt-2017-595]\]. We divided our present cases into group 1 (133 cases, 66.5%), group 2 (55, 27.5%), and group 3 (12, 6.0%) according to our previously proposed criteria for the N category, and demonstrated a statistically significant difference between three groups, similar to results of the N category of the eighth edition (p \< 0.001) ([Fig. 5](#f5-crt-2017-595){ref-type="fig"}). The median survival times of the patients in groups 2 and 3 (18.0 and 17.0 months, respectively) were shorter than that of patients in group 1 (51.8 months; p \< 0.001, each). Meanwhile, there was no significant difference in survival time between the patients in groups 2 and 3 (p=0.765), similar to the results of the N category of the eighth edition. Consequently, further studies are needed to enhance the predictive role of the N category of DBDCs in terms of patient prognosis.

A few previous studies validated T category of the eighth AJCC staging scheme of DBDCs \[[@b13-crt-2017-595],[@b25-crt-2017-595]\]. Moon et al. \[[@b13-crt-2017-595]\] demonstrated the superiority of the eighth edition to the seventh edition for predicting patient prognosis, similar to our study. Kang et al. \[[@b25-crt-2017-595]\] also reported significant survival differences of both pair-wise (T1 vs. T2, T2 vs. T3) and overall comparisons of the eighth edition of the AJCC staging scheme, while no survival difference was observed between T1 and T2 comparison of the seventh edition scheme. In concordance with the previous reports, the results of the present study strongly support that the T category of the eighth edition scheme can discriminate DBDC patients' survival better than the previous scheme.

On applying the depth of invasion in DBDCs, there are important things which pathologists and clinicians should be considered. For the pathologists, invasion to adjacent organs, such as direct spread into the pancreas, duodenum, gallbladder, colon, stomach, or omentum, are recommended to be reported in addition to T category, which was descried in the eighth edition AJCC cancer staging manual \[[@b14-crt-2017-595]\]. For the clinicians, currently preoperative radiologic evaluation for T category of DBDCs is not available due to lack of pathologic-radiologic correlation of depth of invasion of DBDCs. Therefore, further studies of pathologic-radiologic correlation of depth of invasion of DBDCs are required.

Our study has a few limitations. First, the present study was a single institutional study and included 200 cases. Although 200 cases were not small case number for statistical analysis, further multi-institutional or multi-national studies with larger number of cases and longer follow-up period are required for more solid conclusion. Second, no T4 cases were seen in the present study, because all included cases were only surgically resected cases. Therefore, the further study including both surgically resected and unresectable cases is required for survival comparisons between T3 and T4 groups.

In summary, the current eighth edition of the AJCC cancer staging system for DBDCs changed the T and N categories, which enhanced its ability to discriminate patient survival beyond that of the previous scheme of the seventh edition. Further changes are needed for better survival estimation in patients with DBDCs.
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###### 

AJCC staging system for distal bile duct carcinoma

  AJCC seventh edition           AJCC eighth edition                                                                                                                                                         
  ------------------------------ --------------------- ---------------------------------------------------------------------------------------------------------------------------------------------- ------ ------------------------------------------------------------------
  **Primary tumor (T)**                                                                                                                                                                                      
                                 T1                    Tumor confined to the bile duct histologically                                                                                                 T1     Depth of invasion \< 5 mm
                                 T2                    Tumor invades beyond the wall of bile duct                                                                                                     T2     Depth of invasion 5-12 mm
                                 T3                    Tumor invades gallbladder, pancreas, duodenum, or other adjacent organs without involvement of celiac axis or the superior mesenteric artery   T3     Depth of invasion \> 12 mm
                                 T4                    Tumor involves the celiac axis or the superior mesenteric artery                                                                               T4     Tumor involves the celiac axis or the superior mesenteric artery
  **Regional lymph nodes (N)**                                                                                                                                                                               
                                 N0                    No regional lymph node metastasis                                                                                                              N0     No regional lymph node metastasis
                                 N1                    Regional lymph node metastasis                                                                                                                 N1     Metastasis in 1-3 regional lymph nodes
                                                                                                                                                                                                      N2     Metastasis in ≥ 4 regional lymph nodes
  **Distant metastasis (M)**                                                                                                                                                                                 
                                 M0                    No distant metastasis                                                                                                                          M0     No distant metastasis
                                 M1                    Distant metastasis                                                                                                                             M1     Distant metastasis
  **Stage grouping**                                                                                                                                                                                         
                                 IA                    T1N0M0                                                                                                                                         I      T1N0M0
                                 IB                    T2N0M0                                                                                                                                         IIA    T1N1M0 or T2N0M0
                                 IIA                   T3N0M0                                                                                                                                         IIB    T2N1M0 or T3, N0-1, M0
                                 IIB                   T1-3, N1M0                                                                                                                                     IIIA   T1-3, N2M0
                                 III                   T4, any N, M0                                                                                                                                  IIIB   T4, any N, M0
                                 IV                    Any T, any N, M1                                                                                                                               IV     Any T, any N, M1

AJCC, American Joint Committee on Cancer.

###### 

Characteristics of patients with distal bile duct carcinoma

  Variable                                                                 No. (%) (n=200)
  ------------------------------------------------------------------------ -----------------
  **Operation**                                                            
   Pancreatoduodenectomy including Whipple                                 170 (85.0)
   Bile duct resection                                                     30 (15.0)
  **Age, mean±SD (yr)**                                                    65.4±9.2
   \< 60                                                                   55 (27.5)
   ≥ 60                                                                    145 (72.5)
  **Sex**                                                                  
   Male                                                                    137 (68.5)
   Female                                                                  63 (31.5)
  **Location**                                                             
   Intra-pancreatic                                                        168 (84.0)
   Extra-pancreatic                                                        30 (15.0)
   Both intra- and extra-pancreatic                                        2 (1.0)
  **Growth pattern**                                                       
   Papillary                                                               12 (6.0)
   Nodular                                                                 33 (16.5)
   Diffusely infiltrative                                                  155 (77.5)
  **Histologic subtype**                                                   
   Tubular adenocarcinoma                                                  198 (99.0)
   Mucinous carcinoma                                                      1 (0.5)
   Undifferentiated carcinoma                                              1 (0.5)
  **Grade**                                                                
   Low                                                                     167 (83.5)
   High                                                                    33 (16.5)
  **Size, mean±SD (cm)**                                                   2.9±1.2
   \< 2                                                                    39 (19.5)
   2-4                                                                     132 (66.0)
   \> 4                                                                    29 (14.5)
  **Pancreatic invasion^[a)](#tfn1-crt-2017-595){ref-type="table-fn"}^**   
   No                                                                      53 (31.2)
   Yes                                                                     117 (68.8)
  **Duodenal invasion^[a)](#tfn1-crt-2017-595){ref-type="table-fn"}^**     
   No                                                                      116 (68.2)
   Yes                                                                     54 (31.8)
  **Cystic duct of gallbladder invasion**                                  
   No                                                                      163 (81.5)
   Yes                                                                     37 (18.5)
  **Resection margin status of the bile duct**                             
   No involvement                                                          160 (80.0)
   Involved by cancer                                                      40 (20.0)
  **Lymphovascular invasion**                                              81 (40.5)
  **Perineural invasion**                                                  166 (83.0)
  **T category, seventh edition**                                          
   T1                                                                      12 (6.0)
   T2                                                                      40 (20.0)
   T3                                                                      148 (74.0)
   T4                                                                      0
  **N category, seventh edition**                                          
   N0                                                                      133 (66.5)
   N1                                                                      67 (33.5)
  **AJCC stage grouping, seventh edition**                                 
   IA                                                                      12 (6.0)
   IB                                                                      33 (16.5)
   IIA                                                                     88 (44.0)
   IIB                                                                     67 (33.5)
   III                                                                     0
   IV                                                                      0
  **Depth of invasion, mean±SD (mm)**                                      9.3±5.0
  **Total nodes assessed, mean±SD**                                        12.1±7.5
  **No. of positive nodes, mean±SD**                                       0.9±1.9
  **T category, eighth edition**                                           
   T1                                                                      37 (18.5)
   T2                                                                      114 (57.0)
   T3                                                                      49 (24.5)
   T4                                                                      0
  **N category, eighth edition**                                           
   N0                                                                      133 (66.5)
   N1                                                                      50 (25.0)
   N2                                                                      17 (8.5)
  **AJCC stage grouping, eighth edition**                                  
   I                                                                       33 (16.5)
   IIA                                                                     85 (42.5)
   IIB                                                                     65 (32.5)
   IIIA                                                                    17 (8.5)
   IIIB                                                                    0
   IV                                                                      0

SD, standard deviation; AJCC, American Joint Committee on Cancer.

Calculated using only patients with sufficient available data.

###### 

Association between T and N categories of the eighth AJCC and clinicopathologic factors in distal bile duct carcinoma patients

  Clinicopathologic factor                                                 T category   N category                                                                                                                                 
  ------------------------------------------------------------------------ ------------ --------------------------------------------------------- ----------- ---------- --------------------------------------------------------- ----------
  **No. of patients**                                                      37 (18)      114 (57)                                                  49 (25)     133 (67)   50 (25)                                                   17 (8)
  **Age, mean±SD (yr)**                                                    65.5±8.2     66.0±9.1                                                  64.0±10.1   65.3±9.4   65.9±9.2                                                  64.3±7.8
   p-value                                                                              0.453                                                                            0.815                                                     
  **Age (yr)**                                                                                                                                                                                                                     
   \< 60                                                                   9 (24)       27 (24)                                                   19 (39)     36 (27)    15 (30)                                                   4 (23)
   ≥ 60                                                                    28 (76)      87 (76)                                                   30 (61)     97 (73)    35 (70)                                                   13 (77)
   p-value                                                                              0.126                                                                            0.859                                                     
  **Sex**                                                                                                                                                                                                                          
   Male                                                                    25 (68)      76 (67)                                                   36 (74)     92 (69)    34 (68)                                                   11 (65)
   Female                                                                  12 (32)      38 (33)                                                   13 (26)     41 (31)    16 (32)                                                   6 (35)
   p-value                                                                              0.686                                                                            0.929                                                     
  **Location**                                                                                                                                                                                                                     
   Intra-pancreatic                                                        7 (19)       20 (17)                                                   3 (6)       18 (13)    11 (22)                                                   1 (6)
   Extra-pancreatic                                                        30 (81)      93 (82)                                                   45 (92)     115 (87)   38 (76)                                                   15 (88)
   Both intra- and extra-pancreatic                                        0            1 (1)                                                     1 (2)       0          1 (2)                                                     1 (6)
   p-value                                                                              0.202                                                                            0.052                                                     
  **Growth pattern**                                                                                                                                                                                                               
   Papillary                                                               10 (27)      1 (1)                                                     1 (2)       10 (7)     0                                                         2 (12)
   Nodular                                                                 7 (19)       21 (18)                                                   5 (10)      21 (16)    8 (16)                                                    4 (23)
   Diffusely infiltrative                                                  20 (54)      92 (81)                                                   43 (88)     102 (77)   42 (84)                                                   11 (65)
   p-value                                                                              \< 0.001^[a)](#tfn2-crt-2017-595){ref-type="table-fn"}^                          0.130                                                     
  **Size (cm)**                                                                                                                                                                                                                    
   \< 2                                                                    11 (30)      26 (23)                                                   2 (4)       32 (24)    6 (12)                                                    1 (6)
   2-4                                                                     22 (59)      70 (61)                                                   40 (82)     83 (62)    37 (74)                                                   12 (71)
   ≥ 4                                                                     4 (11)       18 (16)                                                   7 (14)      18 (14)    7 (14)                                                    4 (23)
   p-value                                                                              0.022^[a)](#tfn2-crt-2017-595){ref-type="table-fn"}^                             0.172                                                     
  **Histological subtype**                                                                                                                                                                                                         
   Tubular adenocarcinoma                                                  37 (100)     114 (100)                                                 47 (96)     132 (99)   50 (100)                                                  16 (94)
   Mucinous carcinoma                                                      0            0                                                         1 (2)       0          0                                                         1 (6)
   Undifferentiated carcinoma                                              0            0                                                         1 (2)       1 (1)      0                                                         0 (
   p-value                                                                              0.184                                                                            0.163                                                     
  **Grade**                                                                                                                                                                                                                        
   Low                                                                     33 (89)      96 (84)                                                   38 (78)     113 (85)   42 (84)                                                   12 (71)
   High                                                                    4 (11)       18 (16)                                                   11 (22)     20 (15)    8 (16)                                                    5 (29)
   p-value                                                                              0.338                                                                            0.321                                                     
  **Resection margin status of the bile duct**                                                                                                                                                                                     
   No involvement                                                          33 (89)      91 (80)                                                   36 (74)     111 (84)   35 (70)                                                   14 (82)
   Involved by cancer                                                      4 (11)       23 (20)                                                   13 (26)     22 (16)    15 (30)                                                   3 (18)
   p-value                                                                              0.196                                                                            0.124                                                     
  **Lymphovascular invasion**                                                                                                                                                                                                      
   No                                                                      29 (78)      71 (62)                                                   19 (39)     90 (68)    24 (48)                                                   5 (29)
   Yes                                                                     8 (22)       43 (38)                                                   30 (61)     43 (32)    26 (52)                                                   12 (71)
   p-value                                                                              0.001^[a)](#tfn2-crt-2017-595){ref-type="table-fn"}^                             0.002^[a)](#tfn2-crt-2017-595){ref-type="table-fn"}^      
  **Perineural invasion**                                                                                                                                                                                                          
   No                                                                      15 (40)      13 (11)                                                   6 (12)      28 (21)    5 (10)                                                    1 (6)
   Yes                                                                     22 (60)      101 (89)                                                  43 (88)     105 (79)   45 (90)                                                   16 (94)
   p-value                                                                              \< 0.001^[a)](#tfn2-crt-2017-595){ref-type="table-fn"}^                          0.092                                                     
  **Pancreatic invasion^[b)](#tfn3-crt-2017-595){ref-type="table-fn"}^**                                                                                                                                                           
   No                                                                      20 (67)      27 (29)                                                   6 (13)      43 (37)    8 (20)                                                    2 (12)
   Yes                                                                     10 (33)      67 (71)                                                   40 (87)     72 (63)    31 (80)                                                   14 (88)
   p-value                                                                              \< 0.001^[a)](#tfn2-crt-2017-595){ref-type="table-fn"}^                          0.034^[a)](#tfn2-crt-2017-595){ref-type="table-fn"}^      
  **Duodenal invasion^[b)](#tfn3-crt-2017-595){ref-type="table-fn"}^**                                                                                                                                                             
   No                                                                      28 (93)      70 (75)                                                   18 (39)     89 (77)    22 (56)                                                   5 (31)
   Yes                                                                     2 (7)        24 (25)                                                   28 (61)     26 (23)    17 (44)                                                   11 (69)
   p-value                                                                              \< 0.001^[a)](#tfn2-crt-2017-595){ref-type="table-fn"}^                          \< 0.001^[a)](#tfn2-crt-2017-595){ref-type="table-fn"}^   
  **N category, eighth edition**                                                                                                                                                                                                   
   N0                                                                      33 (89)      81 (71)                                                   19 (39)     \-         \-                                                        \-
   N1 (1-3)                                                                4 (11)       26 (23)                                                   20 (41)     \-         \-                                                        \-
   N2 (≥ 4)                                                                0            7 (6)                                                     10 (20)     \-         \-                                                        \-
   p-value                                                                              \< 0.001^[a)](#tfn2-crt-2017-595){ref-type="table-fn"}^                          \-                                                        

Values are presented as number (%) or mean±standard deviation. AJCC, American Joint Committee on Cancer; SD, standard deviation.

Statistically significant (p \< 0.05),

Calculated using only patients with sufficient available data.

###### 

Univariate and multivariate analysis of distal bile duct carcinoma patients

  Variable                                        Univariate analysis   Multivariate analysis                                                                                         
  ----------------------------------------------- --------------------- ----------------------- ---------- --------------------------------------------------------- ----- ---------- ------------------------------------------------------
  **Location**                                                                                             0.098                                                                      
   Extra-pancreatic                               23.2                  \-                      \-         \-                                                                         
   Intra-pancreatic                               44.7                  0.6                     0.4-1.0    0.041^[a)](#tfn4-crt-2017-595){ref-type="table-fn"}^                       
   Both intra- and extra-pancreatic               0                     1.4                     0.3-5.9    0.662                                                                      
  **Growth pattern**                                                                                       0.001^[a)](#tfn4-crt-2017-595){ref-type="table-fn"}^                       0.070
   Papillary                                      55.6                  \-                      \-         \-                                                        \-    \-         \-
   Nodular                                        64.8                  1.2                     0.4-3.6    0.808                                                     1.5   0.3-7.5    0.626
   Diffusely infiltrative                         30.6                  2.9                     1.1-7.8    0.041^[a)](#tfn4-crt-2017-595){ref-type="table-fn"}^      2.8   0.7-12.4   0.168
  **Size (cm)**                                                                                            0.082                                                                      
   \< 2                                           54.6                  \-                      \-         \-                                                                         
   2-4                                            35.4                  1.5                     0.9-2.5    0.146                                                                      
   \> 4                                           25.0                  2.1                     1.1-4.0    0.026^[a)](#tfn4-crt-2017-595){ref-type="table-fn"}^                       
  **Involvement of bile duct margin by cancer**   18.2                  2.1                     1.4-3.1    0.001^[a)](#tfn4-crt-2017-595){ref-type="table-fn"}^      1.3   0.7-2.4    0.340
  **Lymphovascular invasion**                     33.9                  1.5                     1.1-2.2    0.022^[a)](#tfn4-crt-2017-595){ref-type="table-fn"}^      1.5   1.0-2.3    0.085
  **Pancreatic invasion**                         33.9                  3.4                     2.0-5.9    \< 0.001^[a)](#tfn4-crt-2017-595){ref-type="table-fn"}^   2.3   1.3-4.0    0.006^[a)](#tfn4-crt-2017-595){ref-type="table-fn"}^
  **Duodenal invasion**                           32.2                  1.9                     1.3-2.9    0.003^[a)](#tfn4-crt-2017-595){ref-type="table-fn"}^      0.9   0.6-1.6    0.804
  **T category (eighth AJCC)**                                                                             \< 0.001^[a)](#tfn4-crt-2017-595){ref-type="table-fn"}^                    0.014^[a)](#tfn4-crt-2017-595){ref-type="table-fn"}^
   T1 (\< 5 mm)                                   59.3                  \-                      \-         \-                                                        \-    \-         \-
   T2 (5-12 mm)                                   42.4                  2.3                     1.2-4.3    0.013^[a)](#tfn4-crt-2017-595){ref-type="table-fn"}^      1.6   0.7-4.0    0.281
   T3 (\> 12 mm)                                  12.2                  5.2                     2.6-10.1   \< 0.001^[a)](#tfn4-crt-2017-595){ref-type="table-fn"}^   3.0   1.2-7.7    0.023^[a)](#tfn4-crt-2017-595){ref-type="table-fn"}^
  **N category (eighth AJCC)**                                                                             \< 0.001^[a)](#tfn4-crt-2017-595){ref-type="table-fn"}^                    0.029^[a)](#tfn4-crt-2017-595){ref-type="table-fn"}^
   N0                                             47.3                  \-                      \-         \-                                                        \-    \-         \-
   N1 (1-3)                                       17.0                  2.5                     1.7-3.8    \< 0.001^[a)](#tfn4-crt-2017-595){ref-type="table-fn"}^   1.7   1.1-2.8    0.030^[a)](#tfn4-crt-2017-595){ref-type="table-fn"}^
   N2 (≥ 4)                                       14.7                  3.1                     1.7-5.6    \< 0.001^[a)](#tfn4-crt-2017-595){ref-type="table-fn"}^   2.2   1.1-4.3    0.024^[a)](#tfn4-crt-2017-595){ref-type="table-fn"}^

5-YSR, 5-year survival rate; HR, relative hazards ratio; CI, confidence interval; AJCC, American Joint Committee on Cancer.

Statistically significant (p \< 0.05).
